AGEN vs. SGMO, CRIS, OMGA, ZURA, DBVT, BCAB, CLLS, MOLN, CRDL, and OTLK
Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Sangamo Therapeutics (SGMO), Curis (CRIS), Omega Therapeutics (OMGA), Zura Bio (ZURA), DBV Technologies (DBVT), BioAtla (BCAB), Cellectis (CLLS), Molecular Partners (MOLN), Cardiol Therapeutics (CRDL), and Outlook Therapeutics (OTLK). These companies are all part of the "biological products, except diagnostic" industry.
Sangamo Therapeutics (NASDAQ:SGMO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking.
Sangamo Therapeutics has a net margin of -146.30% compared to Sangamo Therapeutics' net margin of -164.69%. Sangamo Therapeutics' return on equity of 0.00% beat Agenus' return on equity.
Sangamo Therapeutics presently has a consensus price target of $4.93, indicating a potential upside of 865.12%. Agenus has a consensus price target of $130.00, indicating a potential upside of 2,307.41%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than Sangamo Therapeutics.
Sangamo Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Agenus received 25 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 70.05% of users gave Agenus an outperform vote while only 62.75% of users gave Sangamo Therapeutics an outperform vote.
In the previous week, Agenus had 11 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 11 mentions for Agenus and 0 mentions for Sangamo Therapeutics. Agenus' average media sentiment score of 0.00 beat Sangamo Therapeutics' score of -0.25 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 3.0% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Agenus has lower revenue, but higher earnings than Sangamo Therapeutics. Agenus is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Agenus beats Sangamo Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Agenus News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
